WO2002011665A3 - Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles - Google Patents

Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles Download PDF

Info

Publication number
WO2002011665A3
WO2002011665A3 PCT/FR2001/002579 FR0102579W WO0211665A3 WO 2002011665 A3 WO2002011665 A3 WO 2002011665A3 FR 0102579 W FR0102579 W FR 0102579W WO 0211665 A3 WO0211665 A3 WO 0211665A3
Authority
WO
WIPO (PCT)
Prior art keywords
nonsteroidal anti
purine
sexual dysfunction
inflammatory drug
association
Prior art date
Application number
PCT/FR2001/002579
Other languages
English (en)
Other versions
WO2002011665A2 (fr
Inventor
Philippe Gorny
Catherine Pons-Himbert
Olivier Stuecker
Original Assignee
Philippe Gorny
Catherine Pons-Himbert
Olivier Stuecker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philippe Gorny, Catherine Pons-Himbert, Olivier Stuecker filed Critical Philippe Gorny
Priority to CA002419042A priority Critical patent/CA2419042A1/fr
Priority to JP2002517003A priority patent/JP2004505897A/ja
Priority to EP01963079A priority patent/EP1309331A2/fr
Priority to AU2001284125A priority patent/AU2001284125A1/en
Priority to IL15421501A priority patent/IL154215A0/xx
Priority to BR0112830-2A priority patent/BR0112830A/pt
Publication of WO2002011665A2 publication Critical patent/WO2002011665A2/fr
Publication of WO2002011665A3 publication Critical patent/WO2002011665A3/fr
Priority to US10/360,354 priority patent/US20030139371A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Médicament comprenant en association, dans un excipient et/ou un véhicule pharmaceutique, une purine et un anti-inflammatoire non stéroïdien (AINS). Les AINS potentialisent l'action des purines dans la prévention ou le traitement des dysfonctions sexuelles masculines ou féminines.
PCT/FR2001/002579 2000-08-08 2001-08-08 Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles WO2002011665A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002419042A CA2419042A1 (fr) 2000-08-08 2001-08-08 Medicament destine notamment a combattre les dysfonctions sexuelles
JP2002517003A JP2004505897A (ja) 2000-08-08 2001-08-08 特に性機能障害を抑えるための薬剤
EP01963079A EP1309331A2 (fr) 2000-08-08 2001-08-08 Medicament pour le traitement des dysfonctions sexuelles
AU2001284125A AU2001284125A1 (en) 2000-08-08 2001-08-08 Medicine for fighting against sexual dysfunction
IL15421501A IL154215A0 (en) 2000-08-08 2001-08-08 Medicine for fighting against sexual dysfunction
BR0112830-2A BR0112830A (pt) 2000-08-08 2001-08-08 Medicamento destinado especialmente a combater as disfunções sexuais
US10/360,354 US20030139371A1 (en) 2000-08-08 2003-02-07 Drug for combating sexual dysfunctions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/10435 2000-08-08
FR0010435A FR2812812B1 (fr) 2000-08-08 2000-08-08 Medicament destine notamment a combattre les dysfonctions sexuelles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/360,354 Continuation US20030139371A1 (en) 2000-08-08 2003-02-07 Drug for combating sexual dysfunctions

Publications (2)

Publication Number Publication Date
WO2002011665A2 WO2002011665A2 (fr) 2002-02-14
WO2002011665A3 true WO2002011665A3 (fr) 2002-08-08

Family

ID=8853401

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/FR2001/002580 WO2002011735A2 (fr) 2000-08-08 2001-08-08 Association, d'une purine et d'un ains pour le traitement des dysfonctions sexuelles
PCT/FR2001/002579 WO2002011665A2 (fr) 2000-08-08 2001-08-08 Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002580 WO2002011735A2 (fr) 2000-08-08 2001-08-08 Association, d'une purine et d'un ains pour le traitement des dysfonctions sexuelles

Country Status (13)

Country Link
US (2) US20030139368A1 (fr)
EP (2) EP1309331A2 (fr)
JP (2) JP2004505897A (fr)
CN (2) CN1496265A (fr)
AU (2) AU2001284126A1 (fr)
BR (2) BR0112830A (fr)
CA (2) CA2420066A1 (fr)
FR (1) FR2812812B1 (fr)
IL (2) IL154216A0 (fr)
NZ (1) NZ523906A (fr)
RU (2) RU2003105601A (fr)
WO (2) WO2002011735A2 (fr)
ZA (2) ZA200300967B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585850B2 (en) * 2004-02-10 2009-09-08 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
JP2008106064A (ja) * 2006-09-28 2008-05-08 Honda Trading Corp ｔ−ＰＡ亢進物質及びその製造方法
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination
WO2011158904A1 (fr) * 2010-06-18 2011-12-22 株式会社林原生物化学研究所 Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif
WO2012145098A1 (fr) * 2011-04-21 2012-10-26 Saint Louis University Utilisation d'agonistes du récepteur à l'adénosine a3 pour le traitement de la douleur neuropathique
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
MA40687A (fr) * 2014-04-10 2017-03-28 Ifom Fondazione St Firc Di Oncologia Molecolare Méthodes et compositions de traitement de malformation vasculaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
WO1997039760A1 (fr) * 1996-04-23 1997-10-30 Queen's University At Kingston Therapie d'association pour le traitement des troubles de l'erection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8379182A (en) * 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
US5847003A (en) * 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
WO1997039760A1 (fr) * 1996-04-23 1997-10-30 Queen's University At Kingston Therapie d'association pour le traitement des troubles de l'erection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORNMAN M S ET AL: "Effect of single dose aspirin on the development of penile hypercoagulability during erection.", BRITISH JOURNAL OF UROLOGY, (1987 MAR) 59 (3) 267-71., XP000998075 *

Also Published As

Publication number Publication date
CA2419042A1 (fr) 2002-02-14
BR0112830A (pt) 2003-06-24
CN1496265A (zh) 2004-05-12
JP2004505897A (ja) 2004-02-26
FR2812812B1 (fr) 2002-10-11
BR0112908A (pt) 2003-06-24
WO2002011735A3 (fr) 2002-08-08
FR2812812A1 (fr) 2002-02-15
JP2004505921A (ja) 2004-02-26
ZA200300966B (en) 2004-02-09
CN1468104A (zh) 2004-01-14
NZ523906A (en) 2004-09-24
AU2001284125A1 (en) 2002-02-18
WO2002011735A2 (fr) 2002-02-14
EP1311273A2 (fr) 2003-05-21
CA2420066A1 (fr) 2002-02-14
US20030139368A1 (en) 2003-07-24
ZA200300967B (en) 2004-02-25
IL154215A0 (en) 2003-07-31
EP1309331A2 (fr) 2003-05-14
WO2002011665A2 (fr) 2002-02-14
US20030139371A1 (en) 2003-07-24
IL154216A0 (en) 2003-07-31
AU2001284126A1 (en) 2002-02-18
RU2003105601A (ru) 2004-09-10
RU2003105600A (ru) 2004-08-10

Similar Documents

Publication Publication Date Title
AU6158001A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
AP2001002125A0 (en) Controlled-rease pharmaceutical formulations.
CA2275554A1 (fr) Formulations intranasales pour traiter les troubles sexuels
PL331822A1 (en) Application of a chelating agent clioquinole in production of a pharmaceutic agent designed for use in treatment of alzheimer disease
IL155795A0 (en) Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
WO2002011665A3 (fr) Association d'une purine et d'un ains pour le traitement des dysfonctions sexuelles
MXPA04002714A (es) Uso de derivados de 2-oxo-1-pirrolidina para el tratamiento de trastornos del movimiento y de la discinesia.
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
EP1448194A4 (fr) Forme posologique contenant de l'apomorphine pour l'amelioration de la dyserection male
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
EP0951908A3 (fr) Methode de traitement de l'impuissance due à des lésions de la moelle épinière
WO2001080860A3 (fr) Traitement quotidien de la dyserection utilisant un inhibiteur de pde5
HUP0400924A3 (en) Use of 2,5-dihydroxybenzenesulfphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
WO2007010337A3 (fr) Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
WO2003024445A1 (fr) Medicaments comprenant un antithrombotique en association avec un derive pyrazolone
WO2001076590A3 (fr) Traitement de la lombalgie benigne liee a la position
WO2005051368A3 (fr) Formulations inhibitrices de la phosphodiesterase v
WO2001062263A3 (fr) Traitement du syndrome de la douleur pelvienne chronique chez l'homme
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU6274101A (en) Medicines for the prevention and treatment of neurodegenerative diseases
WO2003013655A3 (fr) Inhibiteur d'anhydrase carbonique
WO2003013577A3 (fr) Utilisation d'inhibiteurs de il-18 pour le traitement de troubles d'hypersensibilite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 523905

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 154215

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 154/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002517003

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/00967

Country of ref document: ZA

Ref document number: 200300967

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001284125

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001963079

Country of ref document: EP

Ref document number: 2419042

Country of ref document: CA

Ref document number: 10360354

Country of ref document: US

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

Ref document number: 2003105601

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 018170404

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001963079

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001963079

Country of ref document: EP